Pluri Inc. launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors ­ a significant medical need which currently lacks effective treatments. Leveraging two decades of cell expansion expertise and its proprietary technology, Pluri recently unveiled a novel method for expansion of immune cells as well as a new U.S. granted patent. Pluri believes that the newly announced immunotherapy platform can revolutionize solid tumor treatment and unlock the potential of placental MAIT cells, which are unique immune cells derived from healthy donors.

Pluri's Placental Allogeneic MAIT Platform (MAIT) Offering substantial potential benefits compared to conventional T cells, Pluri's MAIT cells are isolated from the human placenta, a source rich in highly potent allogeneic immune cells. These cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional T cells typically collected from peripheral blood, Pluri's MAIT cells demonstrate a lower alloreactivity profile.

This characteristic not only minimizes their likelihood of inducing Graft versus Host Disease (GvHD) - a significant advantage over other potential allogeneic products - but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy. When combined with Pluri's 3D cell expansion technology, the MAIT platform will enable commercial scale production of powerful immune cells as a potential first-in-class, ready to use, off-the-shelf therapy for cancer patients.